Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc ACORQ

Healthcare Biotechnology
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa... see more

Recent & Breaking News (OTCPK:ACORQ)

Acorda Therapeutics Recognized as One of the Best Places to Work in New York State for Third Consecutive Year

Business Wire May 6, 2013

Acorda Therapeutics Reports First Quarter 2013 Financial Results

Business Wire May 2, 2013

Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2013 Financial Results on May 2, 2013

Business Wire April 25, 2013

Mayo Clinic and Acorda Therapeutics Announce Initiation of Phase 1 Trial of Remyelinating Antibody in People with Multiple Sclerosis

Business Wire April 23, 2013

Free Research Reports on ACI, ACOR, C and NEM Issued by the Bedford Report

Marketwired April 16, 2013

Acorda Therapeutics Announces Positive AMPYRA® (dalfampridine) Phase 2 Data in People with Post-Stroke Deficits

Business Wire April 15, 2013

Diazepam Nasal Spray Demonstrates Comparable Bioavailability to Diazepam Rectal Gel in Pharmacokinetic Study

Business Wire March 20, 2013

Acorda to Present New Research on Novel Multiple Sclerosis and Epilepsy Therapies at American Academy of Neurology 65th Annual Meeting

Business Wire March 13, 2013

Data from First Clinical Trial of GGF2 in Heart Failure Presented at the American College of Cardiology 62nd Annual Scientific Session

Business Wire March 7, 2013

Acorda Therapeutics to Present at the Cowen & Company 33rd Annual Health Care Conference

Business Wire February 25, 2013

Acorda Therapeutics to Present at RBC Capital Markets and Citi 2013 Global Healthcare Conferences

Business Wire February 19, 2013

Acorda Therapeutics Announces Company Intranet Named One of Ten Best in the World

Business Wire February 14, 2013

Acorda Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results

Business Wire February 13, 2013

Acorda Therapeutics Presents GGF2 Preclinical Stroke Data at International Stroke Conference

Business Wire February 7, 2013

Acorda Therapeutics to Present at Leerink Swann Global Healthcare Conference

Business Wire February 7, 2013

Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2012 Financial Results on February 13, 2013

Business Wire February 6, 2013

Free Research Report on ABIOMED, Inc., Acco Brands Corp., Acorda Therapeutics, Inc., Addus HomeCare Corp and First Majestic Silver Corp.

PR Newswire January 31, 2013

Acorda Therapeutics Announces Department of Defense Contract to Support Study of AC105 in Acute Spinal Cord Injury

Business Wire January 24, 2013

Acorda Therapeutics Provides Corporate Update at 31st Annual J.P. Morgan Healthcare Conference

Business Wire January 7, 2013

Biotech Industry Experiencing More FDA New Drug Approvals in 2012

Marketwired January 4, 2013